Q-omics provides the consensus-scored PRAMEF12 profile across patient tissues and cancer cell-line models. PRAMEF12 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in UCEC. Additionally, PRAMEF12 RNA expression shows 8,229 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, and TGCT as cancer lineages where PRAMEF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PRAMEF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PRAMEF12 survival associations across molecular data types. PRAMEF12 RNA expression shows survival associations in the most cancer types (17), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PRAMEF12 RNA expression–survival associations across cancer types. High PRAMEF12 expression shows unfavorable associations in UCEC, BLCA, UCS, CHOL and DLBC, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for PRAMEF12 RNA expression.
This table shows molecular features associated with PRAMEF12 in patient tissues and cancer cell lines. In patient samples, PRAMEF12 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, PRAMEF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
